Skip to main content
SpringerLink
Log in

Risk Stratification for Prevention of Sudden Cardiac Death

  • Coronary Artery Disease (PH Stone, Section Editor)
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Sudden cardiac death (SCD) is a very prevalent cause of death in the United States. The majority of individuals who experience SCD do not survive the episode. Although there are ongoing efforts to improve resuscitation (ie, training in cardiopulmonary resuscitation, easy access to automatic external defibrillators), the primary modality addressing this public health problem is prevention by identification and treatment of high-risk cohorts. Current screening techniques have focused on identifying patients for primary prevention of ventricular tachyarrhythmias. Primary prevention therapies include medications, such as beta-blockers, statins, and angiotensin-converting enzyme inhibitors, and the implantable cardioverter defibrillator (ICD), whose use is currently focused on only the highest-risk subpopulations. The high-risk groups that are currently screened for consideration of an ICD for either primary or secondary prevention of SCD include those with a variety of cardiomyopathies, those with a history of previous aborted SCD, and those with genetic predispositions. In patients with ischemic cardiomyopathy and nonischemic dilated cardiomyopathy, the primary screening parameter to identify the highest-risk group (which is then subsequently screened for consideration of an ICD) is left ventricular ejection fraction (LVEF). Various other clinical factors and noninvasive test results are often combined with this information, but the optimal way in which this should be done has not been established. The array of noninvasive tests available includes those focusing on depolarization abnormalities, repolarization abnormalities, disturbed autonomic responses, and imaging. Unfortunately, current risk-stratification paradigms do not identify the majority of patients who will experience SCD. The fundamental reason for this is that the risk of SCD is truly lower in those without high-risk features such as depressed LVEF; however, the much larger number of patients with these lower-risk features translates into a larger absolute number of SCDs in this lower-risk group. In order to widen the scope of risk stratification, careful clinical study will be needed to develop appropriate testing strategies that can reliably identify patients at significant risk for ventricular tachyarrhythmias in the broader population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Goldberger JJ, Cain ME, Hohnloser SH, Kadish AH, Knight BP, Lauer MS, et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death: A Scientific Statement From the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. Circulation. 2008;118(14):1497–518. doi:10.1161/circulationaha.107.189375.

    Article  PubMed  Google Scholar 

  2. Chugh SS. Early identification of risk factors for sudden cardiac death. Nat Rev Cardiol. 2010;7(6):318–26. doi:10.1038/nrcardio.2010.52.

    Article  PubMed  Google Scholar 

  3. Pouleur AC, Barkoudah E, Uno H, Skali H, Finn PV, Zelenkofske SL, et al. Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. Circulation. 2010;122(6):597–602. doi:10.1161/circulationaha.110.940619.

    Article  PubMed  Google Scholar 

  4. Pratt CM, Greenway PS, Schoenfeld MH, Hibben ML, Reiffel JA. Exploration of the precision of classifying sudden cardiac death. Implications for the interpretation of clinical trials. Circulation. 1996;93(3):519–24.

    PubMed  CAS  Google Scholar 

  5. Gang UJ, Jons C, Jorgensen RM, Abildstrom SZ, Haarbo J, Messier MD, et al. Heart rhythm at the time of death documented by an implantable loop recorder. Europace. 2010;12(2):254–60. doi:10.1093/europace/eup383.

    Article  PubMed  Google Scholar 

  6. Nichol G, Thomas E, Callaway CW, Hedges J, Powell JL, Aufderheide TP, et al. Regional variation in out-of-hospital cardiac arrest incidence and outcome. JAMA. 2008;300(12):1423–31. doi:10.1001/jama.300.12.1423.

    Article  PubMed  CAS  Google Scholar 

  7. McNally B, Robb R, Mehta M, Vellano K, Valderrama AL, Yoon PW, et al. Out-of-Hospital Cardiac Arrest Surveillance — Cardiac Arrest Registry to Enhance Survival (CARES), United States, October 1, 2005–December 31, 2010. MMWR Surveill Summ. 2011;60(8):1–19.

    PubMed  Google Scholar 

  8. Ko PC, Chen WJ, Lin CH, Ma MH, Lin FY. Evaluating the quality of prehospital cardiopulmonary resuscitation by reviewing automated external defibrillator records and survival for out-of-hospital witnessed arrests. Resuscitation. 2005;64(2):163–9. doi:10.1016/j.resuscitation.2004.08.013.

    Article  PubMed  Google Scholar 

  9. Goldberger JJ, Buxton AE, Cain M, Costantini O, Exner DV, Knight BP, et al. Risk stratification for arrhythmic sudden cardiac death: identifying the roadblocks. Circulation. 2011;123(21):2423–30. doi:10.1161/circulationaha.110.959734.

    Article  PubMed  Google Scholar 

  10. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. New Engl J Med. 1997;337 (22):1576–84. doi:10.1056/NEJM199711273372202.

    Google Scholar 

  11. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101(11):1297–302.

    PubMed  CAS  Google Scholar 

  12. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102(7):748–54.

    PubMed  CAS  Google Scholar 

  13. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21(24):2071–8. doi:10.1053/euhj.2000.2476.

    Article  PubMed  CAS  Google Scholar 

  14. Buxton AE, Lee KL, Hafley GE, Wyse DG, Fisher JD, Lehmann MH, et al. Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: an analysis of patients enrolled in the multicenter unsustained tachycardia trial. Circulation. 2002;106(19):2466–72.

    Article  PubMed  CAS  Google Scholar 

  15. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335(26):1933–40. doi:10.1056/nejm199612263352601.

    Article  PubMed  CAS  Google Scholar 

  16. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–83. doi:10.1056/NEJMoa013474.

    Article  PubMed  Google Scholar 

  17. Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361(15):1427–36. doi:10.1056/NEJMoa0901889.

    Article  PubMed  CAS  Google Scholar 

  18. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351(24):2481–8. doi:10.1056/NEJMoa041489.

    Article  PubMed  CAS  Google Scholar 

  19. Goldberger JJ, Passman R. Implantable cardioverter-defibrillator therapy after acute myocardial infarction. J Am Coll Cardiol. 2009;54(22):2001–5. doi:10.1016/j.jacc.2009.08.018.

    Article  PubMed  Google Scholar 

  20. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37. doi:10.1056/NEJMoa043399.

    Article  PubMed  CAS  Google Scholar 

  21. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151–8. doi:10.1056/NEJMoa033088.

    Article  PubMed  CAS  Google Scholar 

  22. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292(23):2874–9. doi:10.1001/jama.292.23.2874.

    Article  PubMed  CAS  Google Scholar 

  23. McKenna WJ, Behr ER. Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart. 2002;87(2):169–76.

    Article  PubMed  Google Scholar 

  24. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM, Freedman RA, Gettes LS, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. J Am Coll Cardiol. 2008;51(21):e1–e62. doi:10.1016/j.jacc.2008.02.032.

    Article  PubMed  Google Scholar 

  25. Delise P, Allocca G, Marras E, Giustetto C, Gaita F, Sciarra L, et al. Risk stratification in individuals with the Brugada type 1 ECG pattern without previous cardiac arrest: usefulness of a combined clinical and electrophysiologic approach. Eur Hear J. 2010;32(2):169–76. doi:10.1093/eurheartj/ehq381.

    Article  Google Scholar 

  26. Muthappan P, Calkins H. Arrhythmogenic right ventricular dysplasia. Prog Cardiovasc Dis. 2008;51(1):31–43. doi:10.1016/j.pcad.2008.01.002.

    Article  PubMed  Google Scholar 

  27. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010;121(13):1533–41. doi:10.1161/circulationaha.108.840827.

    Article  PubMed  Google Scholar 

  28. Patel HC, Calkins H. Arrhythmogenic right ventricular dysplasia. Curr Treat Options Cardiovasc Med. 2010;12(6):598–613. doi:10.1007/s11936-010-0097-2.

    Article  PubMed  Google Scholar 

  29. Kaufman ES. Mechanisms and clinical management of inherited channelopathies: Long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT syndrome. Hear Rhythm. 2009;6(8):S51–5. doi:10.1016/j.hrthm.2009.02.009.

    Article  Google Scholar 

  30. Brouwer IA, Zock PL, Camm AJ, Bocker D, Hauer RN, Wever EF, et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA. 2006;295(22):2613–9. doi:10.1001/jama.295.22.2613.

    Article  PubMed  CAS  Google Scholar 

  31. Raitt MH, Connor WE, Morris C, Kron J, Halperin B, Chugh SS, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators. JAMA: J Am Med Assoc. 2005;293(23):2884–91. doi:10.1001/jama.293.23.2884.

    Article  CAS  Google Scholar 

  32. Mittleman M, Siscovick D. Physical exertion as a trigger of myocardial infarction and sudden cardiac death. Cardiol Clin. 1996;14(2):263.

    PubMed  CAS  Google Scholar 

  33. Jolliffe JA, Rees K, Taylor RS, Thompson D, Oldridge N, Ebrahim S. Exercise-based rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2001;7:CD001800. doi:10.1002/14651858.cd001800.pub2.

    PubMed  Google Scholar 

  34. Lampert R, Joska T, Burg MM, Batsford WP, McPherson CA, Jain D. Emotional and physical precipitants of ventricular arrhythmia. Circulation. 2002;106(14):1800–5.

    Article  PubMed  Google Scholar 

  35. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295(2):165–71. doi:10.1001/jama.295.2.165.

    Article  PubMed  CAS  Google Scholar 

  36. Sim I, McDonald KM, Lavori PW, Norbutas CM, Hlatky MA. Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation. 1997;96(9):2823–9.

    PubMed  CAS  Google Scholar 

  37. Piccini JP, Berger JS, O’Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J. 2009;30(10):1245–53. doi:10.1093/eurheartj/ehp100.

    Article  PubMed  CAS  Google Scholar 

  38. Mark DB. Cost-Effectiveness of Defibrillator Therapy or Amiodarone in Chronic Stable Heart Failure: Results From the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation. 2006;114(2):135–42. doi:10.1161/circulationaha.105.581884.

    Article  PubMed  CAS  Google Scholar 

  39. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13.

    Google Scholar 

  40. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation. 1996;94(11):2800–6.

    PubMed  CAS  Google Scholar 

  41. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283(10):1295–302.

    Article  PubMed  CAS  Google Scholar 

  42. Group TNMS. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801–7.

    Article  Google Scholar 

  43. Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol. 1997;80(9B):35J–9J.

    Article  PubMed  CAS  Google Scholar 

  44. Olsson G, Wikstrand J, Warnold I, Manger Cats V, McBoyle D, Herlitz J, et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J. 1992;13(1):28–32.

    PubMed  CAS  Google Scholar 

  45. Hallstrom AP, Cobb LA, Yu BH, Weaver WD, Fahrenbruch CE. An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985. Am J Cardiol. 1991;68(10):1025–31.

    Article  PubMed  CAS  Google Scholar 

  46. Rankovic V, Karha J, Passman R, Kadish AH, Goldberger JJ. Predictors of appropriate implantable cardioverter-defibrillator therapy in patients with idiopathic dilated cardiomyopathy. Am J Cardiol. 2002;89(9):1072–6.

    Article  PubMed  Google Scholar 

  47. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353(14):1471–80. doi:10.1056/NEJMsa051989.

    Article  PubMed  CAS  Google Scholar 

  48. Jacq F, Foulldrin G, Savoure A, Anselme F, Baguelin-Pinaud A, Cribier A, et al. A comparison of anxiety, depression and quality of life between device shock and nonshock groups in implantable cardioverter defibrillator recipients. Gen Hosp Psychiatry. 2009;31(3):266–73. doi:10.1016/j.genhosppsych.2009.01.003.

    Article  PubMed  Google Scholar 

  49. Prudente LA, Reigle J, Bourguignon C, Haines DE, DiMarco JP. Psychological indices and phantom shocks in patients with ICD. J Interv Card Electrophysiol. 2006;15(3):185–90. doi:10.1007/s10840-006-9010-z.

    Article  PubMed  Google Scholar 

  50. Larsen GK, Evans J, Lambert WE, Chen Y, Raitt M. Shocks burden and increased mortality in implantable cardioverter defibrillator patients. Heart Rhythm. 2011;8(12):1881–6.

    Google Scholar 

  51. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359(10):1009–17. doi:10.1056/NEJMoa071098.

    Article  PubMed  CAS  Google Scholar 

  52. Lubinski A, Bissinger A, Boersma L, Leenhardt A, Merkely B, Oto A, et al. Determinants of geographic variations in implantation of cardiac defibrillators in the European Society of Cardiology member countries–data from the European Heart Rhythm Association White Book. Europace. 2011;13(5):654–62. doi:10.1093/europace/eur066.

    Article  PubMed  Google Scholar 

  53. Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48(10):1977–85. doi:10.1016/j.jacc.2006.07.049.

    Article  PubMed  Google Scholar 

  54. Bello D, Fieno DS, Kim RJ, Pereles FS, Passman R, Song G, et al. Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. J Am Coll Cardiol. 2005;45(7):1104–8. doi:10.1016/j.jacc.2004.12.057.

    Article  PubMed  Google Scholar 

  55. Fluechter S, Kuschyk J, Wolpert C, Doesch C, Veltmann C, Haghi D, et al. Extent of late gadolinium enhancement detected by cardiovascular magnetic resonance correlates with the inducibility of ventricular tachyarrhythmia in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2010;12:30. doi:10.1186/1532-429x-12-30.

    Article  PubMed  Google Scholar 

Download references

Disclosure

P. Saha: none; J.J. Goldberger is Director of the Path to Improved Risk Stratification, NFP, a not-for-profit think tank on risk stratification for sudden cardiac death.

Author information

Authors and Affiliations

  1. Division of Cardiology, Northwestern University Feinberg School of Medicine, 251 East Huron, Feinberg Pavilion, Chicago, IL, 60611, USA

    Paban Saha MD & Jeffrey J. Goldberger MD

Authors
  1. Paban Saha MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey J. Goldberger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey J. Goldberger MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saha, P., Goldberger, J.J. Risk Stratification for Prevention of Sudden Cardiac Death. Curr Treat Options Cardio Med 14, 81–90 (2012). https://doi.org/10.1007/s11936-011-0160-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-011-0160-7

Keywords

Search

Navigation